This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

General contraindications to combined oral hormonal contraceptive

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

These include:

  • Consent not given.
  • Individuals under 16 years of age and assessed as not competent using Fraser Guidelines.
  • Individuals 16 years of age and over and assessed as lacking capacity to consent.
  • Known or suspected pregnancy.
  • Known hypersensitivity to the active ingredient or to any constituent of the product - see Summary of Product Characteristics
  • Less 21 days after childbirth (for deliveries over 24 weeks gestation)
  • Breastfeeding and less than six weeks postpartum.
  • Not breastfeeding and 3-6 weeks post-partum with other risk factors for venous thromboembolism (VTE).
  • Individuals aged 50 years and over.

Cardiovascular disease

  • Individuals aged 35 years or more and smoking or stopped smoking less than one year ago
  • Body Mass Index (BMI) equal to or greater than 35kg/m2
  • Blood pressure greater than 140/90mmHg or controlled hypertension
  • Multiple risk factors for cardiovascular disease (CVD) (such as smoking, diabetes, hypertension, obesity and dyslipidaemias)
  • Current or past history of ischaemic heart disease, vascular disease, stroke or transient ischaemic attack
  • Current or past history of venous thromboembolism
  • Complicated valvular or congenital heart disease e.g. pulmonary hypertension, history of subacute bacterial endocarditis
  • First degree relative with venous thromboembolism under 45 years of age
  • Known thrombogenic mutations e.g. factor V Leiden, prothrombin mutation, protein S, protein C and antithrombin deficiencies
  • Cardiomyopathy with impaired cardiac function
  • Atrial fibrillation
  • Significant or prolonged immobility.
  • Imminent planned major surgery (COC should be stopped at least 4 weeks prior to planned major surgery or expected period of limited mobility).

Neurological Conditions

  • Current or past history of migraine with neurological symptoms including aura at any age
  • Migraine without aura, first attack when on method of contraception containing an estrogen

Cancers

  • Past or current history of breast cancer
  • Undiagnosed breast mass (for initiation of method only)
  • Carrier of known gene mutations associated with breast cancer e.g. BRCA1or 2
  • Malignant liver tumour (hepatocellular carcinoma)

Gastro-intestinal Conditions

  • Viral hepatitis, acute or flare (for initiation only)
  • Severe decompensated cirrhosis
  • Gall bladder disease, symptomatic, medically treated
  • Gall bladder disease, currently symptomatic
  • Any bariatric or other surgery resulting in malabsorption.
  • Cholestasis (related to past combined hormonal contraceptive use)
  • Benign liver tumour (hepatocellular adenoma)

Other conditions

  • Diabetes with end organ disease (retinopathy, nephropathy, neuropathy)
  • Positive anti-phospholipid antibodies (with or without systemic lupus erythematosus)
  • Organ transplant, with complications
  • Individuals using enzyme-inducing drugs/herbal products or within 4 weeks of stopping them.
  • Known severe renal impairment or acute renal failure
  • Acute porphyria

Interacting medicines (other than enzyme inducers) – see current British National Formulary (BNF) www.bnf.orgor individual product SPC http://www.medicines.org.uk

  • breastfeeding - UKMEC score varies with respect to timing of use of combined hormonal contraception (2)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.